Current stock page

Catalysts

SLS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

SLSSELLAS Life Sciences Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$7.86−$0.17 (−2.12%)

Latest quote

  • Momentum
    55
  • Value
    —
  • Quality
    73
  • Risk resilience
    32
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
—

No upcoming reporting date is available yet.

AIQ Catalyst
AIQ 57/100

Momentum 55/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment -7.82%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 55/100AIQ Edge 9/10 Strong Relative Position
Beat rate
75%
6 of 8 reported periods
Average surprise
+13.1%
Across covered historical reports
Latest result
+0.0%
Nov 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 12, 2026—-$0.05-$0.05+0.0%——
Aug 11, 2026—-$0.05-$0.05-11.1%——
May 12, 2026—-$0.06-$0.05+16.7%——
Mar 19, 2026—-$0.06-$0.05+21.0%——
Nov 12, 2025—-$0.06-$0.06+5.3%——
Aug 12, 2025—-$0.08-$0.07+16.0%——
May 13, 2025—-$0.10-$0.07+30.0%——
Mar 20, 2025—-$0.11-$0.08+27.3%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Strong Buy
2
Buy
12-month analyst target
—
— versus current price
Based on 2 analyst observations. Targets are estimates, not predictions.
No analyst target path in this snapshot.
Low target
—
—
Average target
—
—
High target
—
—

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event date—

Upcoming earnings date not available yet.

Sentiment score—

News pressure around the setup.

Momentum score55

Where event reaction would show up first.

AIQ score57/100

Composite decision read before event confirmation.

Analyst context

Consensus
Strong Buy
Analysts
2

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
2
Negative
2
gurufocus.com · Oct 28, 2026

SELLAS Life Sciences (SLS) Shares Slide After Phase 3 REGAL Trial Milestone

On October 28, 2026, SELLAS Life Sciences Group Inc (NASDAQ: SLS) saw a notable decline in its stock price following the announcement that its Phase 3 REGAL tri

seekingalpha.com · Oct 28, 2026

Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)

Sellas Life Sciences remains a 'Strong Sell,' as the REGAL trial delay signals increased risk of failure and diminished probability of success. Learn more about SLS stock here.

seekingalpha.com · Oct 26, 2026

Sellas Life Sciences: Too Many Survivors For Its Own Trial Plan (NASDAQ:SLS)

Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click to know why I rate SLS stock a Hold.

insidermonkey.com · Oct 1, 2026

Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3

Shares of Sellas Life Sciences Group Inc.

finance.yahoo.com · Sep 1, 2026

Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

Open full news and sentiment

SLS Catalysts FAQ

What are the next catalysts for SLS stock?

SLS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move SLS stock?

Upcoming events that could move SLS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could SLS's next earnings report affect the stock?

SLS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive SLS stock higher?

SLS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt SLS stock?

SLS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.